Update on Targeted Therapy in Medullary Thyroid Cancer.
Update on Targeted Therapy in Medullary Thyroid Cancer.
复制标题
DOI：
10.3389/fendo.2021.708949
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Del Rivero J
中科院分区：
文献类型：
--
作者：
Okafor C;Hogan J;Raygada M;Thomas BJ;Akshintala S;Glod JW;Del Rivero J
甲状腺髓样癌（MTC）是一种罕见的神经内分泌肿瘤，占所有甲状腺癌的2-4%。所有遗传性MTC和大约50%的散发病例都是由转染期间重排（RET）原癌基因的突变驱动的。近年来，靶向RET的酪氨酸激酶抑制剂（TKI）的应用范围不断扩大，为转移性和进展性疾病患者的全身治疗提供了有效的选择。然而，发生耐药疾病的患者以及具有其他分子驱动因素（如RAS）的患者的选择有限。需要更好地理解TKI耐药机制以及识别新的治疗靶点，以改善MTC患者的结局。
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the REarranged during Transfection (RET) proto-oncogene. The recent expansion of the armamentarium of RET-targeting tyrosine kinase inhibitors (TKIs) has provided effective options for systemic therapy for patients with metastatic and progressive disease. However, patients that develop resistant disease as well as those with other molecular drivers such as RAS have limited options. An improved understanding of mechanisms of resistance to TKIs as well as identification of novel therapeutic targets is needed to improve outcomes for patients with MTC.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-11-0933
发表时间：
2011-10-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Jin N;Jiang T;Rosen DM;Nelkin BD;Ball DW
通讯作者：
Ball DW
影响因子：
5.8
作者：
Agrawal, Nishant;Jiao, Yuchen;Ball, Douglas W.
通讯作者：
Ball, Douglas W.
影响因子：
4
作者：
Hobbs, G. Aaron;Der, Channing J.;Rossman, Kent L.
通讯作者：
Rossman, Kent L.
影响因子：
3.2
作者：
Chuk, Meredith K.;Widemann, Brigitte C.;Weigel, Brenda J.
通讯作者：
Weigel, Brenda J.
DOI：
10.1158/1078-0432.ccr-13-0071
发表时间：
2013-08-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Fox E;Widemann BC;Chuk MK;Marcus L;Aikin A;Whitcomb PO;Merino MJ;Lodish M;Dombi E;Steinberg SM;Wells SA;Balis FM
通讯作者：
Balis FM